Plasma lipids (cholesterol, triglycerides, and NEFAs) were all reduced by both doses of rmuFGF21 in WT mice (Figures 1J–L). Interestingly, only cholesterol levels were reduced by rmuFGF21 treatment in Tg mice, albeit to a lesser extent than in WT mice (Figure 1J).